Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
27.22
-0.25 (-0.91%)
At close: Apr 9, 2026, 4:00 PM EDT
27.18
-0.04 (-0.15%)
After-hours: Apr 9, 2026, 5:05 PM EDT
Pfizer Market Cap
Pfizer has a market cap or net worth of $154.84 billion as of April 9, 2026. Its market cap has increased by 4.52% in one year.
Market Cap
154.84B
Enterprise Value
209.66B
1-Year Change
4.52%
Ranking
Category
Stock Price
$27.22
Market Cap Chart
Since December 1, 1998, Pfizer's market cap has increased from $144.06B to $154.84B, an increase of 7.48%. That is a compound annual growth rate of 0.26%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 8, 2026 | 156.20B | 10.33% |
| Dec 31, 2025 | 141.57B | -5.83% |
| Dec 31, 2024 | 150.35B | -7.51% |
| Dec 29, 2023 | 162.56B | -43.48% |
| Dec 30, 2022 | 287.63B | -13.22% |
| Dec 31, 2021 | 331.44B | 61.99% |
| Dec 31, 2020 | 204.60B | -5.64% |
| Dec 31, 2019 | 216.83B | -14.07% |
| Dec 31, 2018 | 252.32B | 16.87% |
| Dec 29, 2017 | 215.90B | 9.54% |
| Dec 30, 2016 | 197.10B | -1.09% |
| Dec 31, 2015 | 199.26B | 1.53% |
| Dec 31, 2014 | 196.27B | -1.13% |
| Dec 31, 2013 | 198.52B | 7.51% |
| Dec 31, 2012 | 184.65B | 11.00% |
| Dec 30, 2011 | 166.35B | 18.60% |
| Dec 31, 2010 | 140.25B | -4.45% |
| Dec 31, 2009 | 146.78B | 22.92% |
| Dec 31, 2008 | 119.42B | -23.08% |
| Dec 31, 2007 | 155.24B | -16.87% |
| Dec 29, 2006 | 186.75B | 8.64% |
| Dec 30, 2005 | 171.90B | -15.11% |
| Dec 31, 2004 | 202.51B | -24.89% |
| Dec 31, 2003 | 269.62B | 43.13% |
| Dec 31, 2002 | 188.38B | -24.81% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Johnson & Johnson | 583.49B |
| AbbVie | 375.21B |
| AstraZeneca | 317.11B |
| Merck & Co. | 303.21B |
| Novartis AG | 292.80B |
| Amgen | 192.28B |
| Gilead Sciences | 176.34B |
| Novo Nordisk | 166.69B |